Talphera outlines 2025 timeline for NEPHRO CRRT study completion and FDA approval of Niyad
CFO Raffi Asadorian reported that Talphera reduced Q4 2024 operating expenses to $3 million from $4.6 million in Q4 2023, with further cash operating expenses for 2025 projected at $18-$19 million.
CNN26d
An airplane foot hammock for comfort? My knees would disagree
As a frequent flyer constantly searching for ways to enhance my in-flight comfort, I was intrigued by the Amazon Basic Concept Airplane Foot Hammock. I was hoping it would make economy class more ...